Julphar’s first introduction for orthopaedists

With its participation in the 4th Emirates International Orthopaedic Congress held in the Event Centre Dubai Festival City from April 21st to 23rd, 2016 Julphar was introduced for the first time in the orthopaedic medical specialty.

The three-day Orthopaedic Congress program – organized by the Emirates Orthopaedic Society Board of the Emirates Medical Association – included numerous sessions focusing on the topics of Joint Replacement and Orthopaedic Oncology – and other orthopaedic subspecialties, and was the opportunity for physicians, researchers and students from around the world to attend an international platform, network with members of the orthopaedic medicine and expand their knowledge of the specialty. During the Congress, leading experts shared updates and news on the latest available orthopaedic-related advanced technology and products, and introduced new ways to manage orthopaedic infections and pain.

“Our participation in the Emirates International Orthopaedic Congress was a good opportunity for Julphar to highlight the company’s portfolio that can support our orthopaedists in improving orthopedic surgery patient’s quality of life”, said Dr. Hosam Badr, Marketing Director at Julphar. “The Congress includes one of the most important scientific programs for the orthopaedic community, and it allowed us to share the benefits of our newly launched product Turox, the fastest once daily Non-Steroidal Anti-inflammatory Drug (NSAD) used for the treatment of painful acute and chronic inflammatory conditions, with the members of the orthopaedic society, as well as to share newest information on our well known product MEBO for wound healing.”

Julphar was one of the Congress sponsors as per its commitment to further explore the medical market and to continuously support healthcare professionals’ continuing education (CME) programs.